The hepatitis B vaccine is one of the most potent immunizations, usually providing decades of protection against the deadly liver virus. But in about 10% of people it doesn’t work, and in 2020, Amy Huei-Yi Lee, a systems biologist at Simon Fraser University, and her colleagues set out to determine whether they could predict who would benefit. The scientists found that data on recipients’ immune systems such as the abundance of certain proteins and the activity patterns of a few genes foretold whether they would generate defenses against the virus. “We got a sense of what factors drive the vaccine response and what [doesn’t],” Lee says.
Trending
- Tenebe, FIFA agent move to boost Bendel Insurance’s global profile ahead of new season
- Farmers turn to insurance against production risks
- UNFPA donates equipment for VVF treatment in Sokoto
- FG directs MDAs to comply with data protection act
- Lagos residents, traders lament soaring egg prices
- Vet urges Nigerians to ignore rabies myths
- Lagos receives new pumps for Iju, Adiyan Waterworks
- Oyo enforces mandatory waste bins from Sept 1
